334 related articles for article (PubMed ID: 34667075)
1. Health care costs of hospitalization of young children for respiratory syncytial virus infections: a population-based matched cohort study.
Thampi N; Knight BD; Thavorn K; Webster RJ; Lanctot K; Hawken S; McNally JD
CMAJ Open; 2021; 9(4):E948-E956. PubMed ID: 34667075
[TBL] [Abstract][Full Text] [Related]
2. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
3. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.
McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL
J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190
[TBL] [Abstract][Full Text] [Related]
4. Burden of illness associated with Respiratory Syncytial Virus (RSV)-related hospitalizations among adults in Ontario, Canada: A retrospective population-based study.
Mac S; Shi S; Millson B; Tehrani A; Eberg M; Myageri V; Langley JM; Simpson S
Vaccine; 2023 Aug; 41(35):5141-5149. PubMed ID: 37422377
[TBL] [Abstract][Full Text] [Related]
5. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA
Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
[TBL] [Abstract][Full Text] [Related]
6. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
Paes B; Steele S; Janes M; Pinelli J
Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
[TBL] [Abstract][Full Text] [Related]
7. Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk.
Rietveld E; De Jonge HC; Polder JJ; Vergouwe Y; Veeze HJ; Moll HA; Steyerberg EW
Pediatr Infect Dis J; 2004 Jun; 23(6):523-9. PubMed ID: 15194833
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost.
Atkins JT; Karimi P; Morris BH; McDavid G; Shim S
Pediatr Infect Dis J; 2000 Feb; 19(2):138-43. PubMed ID: 10694001
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Hampp C; Kauf TL; Saidi AS; Winterstein AG
Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
[TBL] [Abstract][Full Text] [Related]
10. Long-term Assessment of Healthcare Utilization 5 Years After Respiratory Syncytial Virus Infection in US Infants.
Simões EAF; Chirikov V; Botteman M; Kwon Y; Kuznik A
J Infect Dis; 2020 Mar; 221(8):1256-1270. PubMed ID: 31165865
[TBL] [Abstract][Full Text] [Related]
11. Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global Level: A Systematic Review and Meta-Analysis.
Zhang S; Akmar LZ; Bailey F; Rath BA; Alchikh M; Schweiger B; Lucero MG; Nillos LT; Kyaw MH; Kieffer A; Tong S; Campbell H; Beutels P; Nair H;
J Infect Dis; 2020 Oct; 222(Suppl 7):S680-S687. PubMed ID: 32227101
[TBL] [Abstract][Full Text] [Related]
12. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
Régnier SA
Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
[TBL] [Abstract][Full Text] [Related]
13. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
[TBL] [Abstract][Full Text] [Related]
14. Economic analysis of palivizumab in infants with congenital heart disease.
Yount LE; Mahle WT
Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
[TBL] [Abstract][Full Text] [Related]
16. Estimating the Incidence of First RSV Hospitalization in Children Born in Ontario, Canada.
Buchan SA; Chung H; To T; Daneman N; Guttmann A; Kwong JC; Murti M; Aryal G; Campigotto A; Chakraborty P; Gubbay J; Karnauchow T; Katz K; McGeer AJ; Dayre McNally J; Mubareka S; Richardson D; Richardson SE; Smieja M; Zahariadis G; Deeks SL
J Pediatric Infect Dis Soc; 2023 Jul; 12(7):421-430. PubMed ID: 37335754
[TBL] [Abstract][Full Text] [Related]
17. Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis.
Amand C; Tong S; Kieffer A; Kyaw MH
BMC Health Serv Res; 2018 Apr; 18(1):294. PubMed ID: 29678177
[TBL] [Abstract][Full Text] [Related]
18. Costs of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010.
Bhuiyan MU; Luby SP; Alamgir NI; Homaira N; Sturm-Ramirez K; Gurley ES; Abedin J; Zaman RU; Alamgir A; Rahman M; Ortega-Sanchez IR; Azziz-Baumgartner E
J Glob Health; 2017 Jun; 7(1):010412. PubMed ID: 28702175
[TBL] [Abstract][Full Text] [Related]
19. Economic-Burden Trajectories in Commercially Insured US Infants With Respiratory Syncytial Virus Infection.
Chirikov VV; Simões EAF; Kuznik A; Kwon Y; Botteman M
J Infect Dis; 2020 Mar; 221(8):1244-1255. PubMed ID: 30982895
[TBL] [Abstract][Full Text] [Related]
20. Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study.
Papenburg J; Saleem M; Teselink J; Li A; Caouette G; Massé É; Lanctôt KL
Pediatr Infect Dis J; 2020 Aug; 39(8):694-699. PubMed ID: 32379195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
